Mission Bio touts study about its Tapestri platform

By The Science Advisory Board staff writers

November 23, 2021 -- Mission Bio announced that its Tapestri platform helped elucidate resistance mechanisms to lung cancer drugs. Researchers from Memorial Sloan Kettering Cancer Center detail the discovery of these resistance mechanisms in a study that was published November 10 in Nature.

Single-cell DNA sequencing helped reveal the evolution of resistance against KRAS G12C inhibitors like sotorasib, which was approved earlier this year for directly inhibiting a mutation in the RAS family of oncogenes.

The researchers found that the secondary mutations they identified from bulk sequencing often co-occurred with the targeted mutation (KRAS G12C) in the drug-resistant cells (Nature, November 10, 2021).

These secondary mutations within the same cells were shown to circumvent the effect of target KRAS inhibitor therapy by upregulating other players in the pathway. The Tapestri platform allowed the research team to better understand how mutations emerge in individual cells, according to the firm.

Mission Bio debuts new capabilities for cell, gene therapy
Mission Bio has unveiled its Tapestri Cell & Gene Therapy Solutions, a new addition to its Tapesti platform that can provide analytical characterization...
Mission Bio updates platform to expand heme-onc research
Mission Bio has improved its Tapestri platform to expand its accessibility and utility in hematologic oncology (heme-onc) research.

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter